Mirae Asset Global ETFs Holdings
DSGN icon

Mirae Asset Global ETFs Holdings’s Design Therapeutics DSGN Stock Holding History

Mirae Asset Global ETFs Holdings’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$205K Buy
14,171
+2,808
+25% +$35K ﹤0.01% 2470
2026
Q1 		$121K Buy
11,363
+272
+2% +$2.75K ﹤0.01% 2589
2025
Q4 		$104K Buy
11,091
+367
+3% +$2.87K ﹤0.01% 2664
2025
Q3 		$80.8K Sell
10,724
-7,233
-40% -$36.2K ﹤0.01% 2761
2025
Q2 		$60.5K Sell
17,957
-780
-4% -$2.92K ﹤0.01% 2833
2025
Q1 		$72.3K Buy
18,737
+780
+4% +$3.72K ﹤0.01% 2756
2024
Q4 		$111K Buy
17,957
+760
+4% +$4.4K ﹤0.01% 2662
2024
Q3 		$92.5K Buy
17,197
+927
+6% +$4.36K ﹤0.01% 2748
2024
Q2 		$54.5K Buy
+16,270
New +$63.4K ﹤0.01% 2769

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Logos Global Management
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Driehaus Capital Management
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
Frazier Life Sciences Management
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Mirae Asset Global ETFs Holdings's DSGN Position: Q2 2026 in Review

Mirae Asset Global ETFs Holdings increased its Design Therapeutics (DSGN) stake by 25% in Q2 2026, buying an estimated $35K and bringing the position to 14,171 shares worth $205K. The position accounts for ﹤0.01% of the portfolio, ranked #2470.

Mirae Asset Global ETFs Holdings first reported a position in DSGN in Q2 2024 and has held it in 9 quarters since. 136 funds tracked by Wall St. Rank hold DSGN as of Q2 2026.

  • Mirae Asset Global ETFs Holdings held 14,171 shares of Design Therapeutics worth $205K as of Q2 2026.
  • Mirae Asset Global ETFs Holdings bought 2,808 Design Therapeutics shares in Q2 2026, an estimated $35K.
  • Design Therapeutics made up ﹤0.01% of Mirae Asset Global ETFs Holdings's portfolio in Q2 2026, its #2470 holding.
  • Mirae Asset Global ETFs Holdings first reported a position in Design Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • 136 funds tracked by Wall St. Rank held Design Therapeutics as of Q2 2026.

Based on Mirae Asset Global ETFs Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.